Skip to main content

Biomea Fusion Stock Forecast, Price & News

-0.50 (-3.05 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume119,242 shs
Average Volume122,902 shs
Market Capitalization$456.84 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BMEA News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

About Biomea Fusion

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:BMEA
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$456.84 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.70 out of 5 stars

Medical Sector

1066th out of 2,045 stocks

Biotechnology Industry

53rd out of 158 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Biomea Fusion (NASDAQ:BMEA) Frequently Asked Questions

Is Biomea Fusion a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biomea Fusion stock.
View analyst ratings for Biomea Fusion
or view top-rated stocks.

What stocks does MarketBeat like better than Biomea Fusion?

Wall Street analysts have given Biomea Fusion a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biomea Fusion wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for BMEA?

3 brokerages have issued twelve-month price objectives for Biomea Fusion's stock. Their forecasts range from $26.00 to $27.00. On average, they anticipate Biomea Fusion's stock price to reach $26.33 in the next year. This suggests a possible upside of 65.8% from the stock's current price.
View analysts' price targets for Biomea Fusion
or view top-rated stocks among Wall Street analysts.

Who are Biomea Fusion's key executives?

Biomea Fusion's management team includes the following people:
  • Mr. Thomas Butler, CEO, Co-Founder & Director (Age 40)
  • Mr. Ramses M. Erdtmann, Co-Founder, Pres, COO & Director (Age 58)
  • Ms. Sunny Lee Ryan CPA, Exec. VP of Fin. (Age 51)
  • Mr. Heow Tan, Chief Technology & Quality Officer (Age 62)
  • Dr. Thorsten Kirschberg Ph.D., Exec. VP of Chemistry (Age 51)

Who are some of Biomea Fusion's key competitors?

When did Biomea Fusion IPO?

(BMEA) raised $120 million in an IPO on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.

What is Biomea Fusion's stock symbol?

Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA."

When does the company's quiet period expire?

Biomea Fusion's quiet period expires on Wednesday, May 26th. Biomea Fusion had issued 9,000,000 shares in its public offering on April 16th. The total size of the offering was $153,000,000 based on an initial share price of $17.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Biomea Fusion?

Shares of BMEA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomea Fusion's stock price today?

One share of BMEA stock can currently be purchased for approximately $15.88.

How much money does Biomea Fusion make?

Biomea Fusion has a market capitalization of $456.84 million.

How many employees does Biomea Fusion have?

Biomea Fusion employs 12 workers across the globe.

What is Biomea Fusion's official website?

The official website for Biomea Fusion is

How can I contact Biomea Fusion?

The company can be reached via phone at 650-980-9099.

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.